Objective: The objectives of these two studies were to determine if beads from extended-release topiramate capsules sprinkled onto soft food are bioequivalent to the intact capsule and if beads from the capsule can be passed through enteral gastrostomy (G-) and jejunostomy (J-) feeding tubes. Methods: Bioequivalence of 200-mg USL255 (Qudexy® XR [topiramate] extended-release capsules) sprinkled onto soft food (applesauce) versus the intact capsule was evaluated in a phase 1, randomized, single-dose, crossover study (N = 36). Pharmacokinetic evaluations included area under the curve (AUC), maximum plasma concentration (C max ), time to C max (T max ), and terminal elimination half-life (t 1/2 ). If 90% confidence intervals (CI) of the ratio of geometric least-squares means were between 0.80 and 1.25, AUC and C max were considered bioequivalent. In separate in vitro experiments, 100-mg USL255 beads were passed through feeding tubes using gentle syringe pressure to develop a clog-free bead-delivery method. Multiple tube sizes (14-to 18-French [Fr] tubes), dilutions (5 mg/15 mL-25 mg/15 mL), and diluents (deionized water, apple juice, Ketocal, sparkling water) were tested. Results: Area under the curve and C max for USL255 beads sprinkled onto applesauce were bioequivalent to the intact capsule (GLSM [90% CI]: AUC 0-t 1.01 [0.97-1.04], AUC 0-∞ 1.02 [0.98-1.05]; C max 1.09 [1.03-1.14]). Median T max was 4 h earlier for USL255 sprinkled versus the intact capsule (10 vs 14 h; p = 0.0018), and t 1/2 was similar (84 vs 82 h, respectively). In 14-Fr G-tubes, USL255 beads diluted in Ketocal minimized bead clogging versus deionized water. Recovery of USL255 beads diluted in deionized water was nearly 100% in 16-Fr G-, 18-Fr G-, and 18-Fr J-tubes. Significance: For patients with difficulty swallowing pills, USL255 sprinkled onto applesauce offers a useful oncedaily option for taking topiramate. USL255 beads were also successfully delivered in vitro through ≥14-Fr G-or Jtubes, with tube clogging minimized by portioning the dose and using glidant diluents for smaller tubes.
Introduction
The recent influx of new antiepileptic drugs (AEDs) has provided additional options for seizure management [1] ; however, the majority of AEDs are often formulated as capsules or tablets [2] , which may not be suitable treatment options for all patients with epilepsy. The incidence of epilepsy is high in pediatric and elderly patients, who often have trouble swallowing medications [3, 4] . Additionally, patients with epilepsy may suffer from dysphagia as a result of medical conditions that commonly coexist with epilepsy-such as cerebral palsy and intellectual/ physical disabilities [5, 6] . Regardless of their cause, swallowing difficulties in these patients with epilepsy can contribute to suboptimal drug adherence [6] .
Newer AEDs, including extended-release (XR) drugs with less frequent dosing and sprinkle formulations, may provide an improved treatment option for patients with swallowing difficulties, which in turn, may increase medication adherence and seizure control. Newer formulations and alternate delivery options also are needed for the subpopulation of patients with epilepsy in which feeding tubes are surgically implanted [7] due to swallowing difficulties secondary to neurological comorbidities [8] .
USL255, Qudexy® XR (topiramate) extended-release capsules (Upsher-Smith Laboratories, Maple Grove, MN, U.S.A.), is a once-daily, XR formulation of topiramate-a broad-spectrum, well-established AED-available as 25-mg, 50-mg, 100-mg, 150-mg, and 200-mg capsules. In previous phase 1 studies, USL255 displayed dose proportional 
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Epilepsy & Behavior j o u r n a l h o m e p a g e : w w w . e l s e v i e r . c o m / l o c a t e / y e b e h pharmacokinetics (PK) [9] and, compared with immediate-release topiramate dosed twice daily, provided equivalent topiramate exposure with a 26% decreased fluctuation index at steady state [10] . A placebocontrolled, randomized, multinational phase 3 study found that USL255 200 mg was efficacious and generally well tolerated in the adjunctive treatment of partial-onset seizures (POS) [11, 12] . USL255 is approved in the United States in patients ≥2 years of age as monotherapy for POS or primary generalized tonic-clonic (PGTC) seizures, and adjunctive therapy for POS, PGTC seizures, or seizures associated with Lennox-Gastaut syndrome [13] . USL255 is a proprietary multiparticulate (beads in a capsule) formulation that can be swallowed whole or opened and sprinkled onto soft food, which may provide a once-daily alternative for those patients experiencing swallowing difficulties. The purpose of this publication is to present findings from two separate studies that evaluated the clinical utility of USL255 delivery methods. In the first investigation, the bioequivalence of USL255 beads sprinkled onto soft food (applesauce) versus the intact capsule was assessed in a phase 1 study in healthy adults. In the second study, exploratory in vitro experiments were performed to assess the delivery of various dilutions of USL255 beads in multiple diluents passed through enteral gastrostomy (G-tube) and jejunostomy (J-tube) feeding tubes.
Methods
2.1. Bioequivalence of USL255 beads sprinkled onto applesauce versus the intact capsule postovernight fast
Study overview
A phase 1 study in healthy adults was used to assess the bioequivalence of USL255 beads sprinkled onto applesauce (herein referred to as "sprinkled") compared with the intact capsule. This study was conducted in accordance with the International Conference on Harmonisation (ICH) E6, Guideline for Good Clinical Practice (GCP), and all applicable regulatory requirements. The study protocol was reviewed and approved by the IntegReview Institutional Review Board. Prior to randomization, all participants provided written informed consent.
Study design
This was a phase 1, randomized, single-center, open-label, singledose, 4-way crossover study in which 36 healthy adults were enrolled into 1 of 4 treatment sequences (n = 9/sequence), each with 4 treatment periods (21-day minimum washout between treatments). Treatment periods included a single dose of an entire USL255 200-mg capsule sprinkled onto 1 tablespoonful of applesauce after an overnight fast and a single dose of a USL255 200-mg capsule administered intact after an overnight fast. The PK data from two additional USL255-treatment periods do not pertain to the primary objectives of this publication and are, therefore, not included here. Participants were confined to the clinic for at least 36 h pretreatment and 48 h posttreatment.
Study participants
Participants in the phase 1 study were healthy men and women between 18 and 65 years of age, who had a body mass index (BMI) between 18 and 30 kg/m 2 and weighed at least 110 lb. Participants were required to have abstained from consuming alcohol-, caffeine-, and xanthine-containing beverages for 36 h before and 72 h after each dose, and refrained from the use of tobacco products within 90 days before screening and until the final study visit. Participants with a known hypersensitivity to topiramate or any excipient in USL255 as well as hypersensitivity to apples, applesauce, or its constituents were excluded from the study. Additional key exclusion criteria included: a clinically relevant current illness (within 4 weeks before dosing) or clinical history that would interfere with the participant's ability to complete the study or confound the results of this study (as determined by the investigator); a predisposing condition that could interfere with the absorption, distribution, metabolism, or excretion of drugs; prescription medication taken within 14 days before the initial PK study period or taken over-the-counter oral preparations, including dietary and herbal supplements, within 3 days before the initial PK study period; or a history of clinically significant alcohol or drug abuse. Participant demographics, baseline characteristics, and safety/ tolerability analyses were based on the safety population, defined as all randomized participants who received at least 1 dose of study drug. The PK population was defined as all participants who received at least 1 dose of any treatment and for whom sufficient PK samples were collected for accurate estimation of PK parameters. The bioequivalence population was a subset of the PK population and included all participants who completed the treatment periods being compared (i.e., USL255 beads sprinkled vs intact USL255 capsule).
Pharmacokinetic and safety/tolerability analyses
Blood samples were drawn within 1 h predose (0 h), every 2 h until 32 h postdose, and at 36, 48, 72, 96, 120, 168, 216, 264, and 336 h postdose. The PK samples were analyzed for topiramate using high performance liquid chromatography with tandem mass spectrometry (HPLC MS/MS), with a lower limit of quantification of 10 ng/mL as previously described [14] . Standard PK parameters were calculated from the plasma concentration-time data using noncompartmental methods [15] and included area under the plasma concentration-time curve from time zero to time of last quantifiable concentration (AUC 0-t ) calculated by linear trapezoidal rule, AUC from time zero to infinity (AUC 0-∞ ), maximum plasma concentration (C max ), time to C max (T max ), and terminal elimination half-life (t 1/2 ).
Safety and tolerability assessments were conducted at baseline and throughout the study. Treatment-emergent adverse events (TEAEs) reported during the study were categorized by the investigator based on intensity (mild, moderate, severe) and relationship to study drug. Additional evaluations included vital signs, electrocardiogram (ECG) findings, physical examination, and clinical laboratory evaluations (e.g., hematology, serum chemistry, and urinalysis). Suicidality assessment via the Columbia-Suicide Severity Rating Scale (C-SSRS) also was performed at each study check-in, check-out, and final study visit.
Statistical analyses
Bioequivalence for AUC and C max was established if the 90% confidence intervals (CI) for the ratio of geometric least-squares means (GLSM) were contained within the 0.80-1.25 equivalence limits. This methodology is in line with guidance from the US Federal Drug Administration regarding bioequivalence studies. Wilcoxon signedrank test was used for nonparametric comparison of T max values. Descriptive statistics were calculated for the safety and tolerability assessments.
In vitro delivery of USL255 beads via enteral feeding tubes

Study overview
USL255 beads cannot be crushed into a powder or modified prior to dosing, as this may compromise the extended-release characteristics of the drug. Therefore, exploratory in vitro experiments were performed to assess delivery methods to minimize clogging of feeding tubes with intact beads. To determine the optimal method, various dilutions of USL255 beads in multiple diluents were passed through G-and J-tubes using gentle syringe pressure. Tube sizes included 14, 16, and 18 Mic™ French unit (Fr) G-tubes (~25 cm in length) and 18-Fr J-tube (~75 cm in length), where 1 Fr is equal to 0.33 mm. Large-bore (≥ 14 Fr) feeding tubes are preferred for delivering medications [7] , and the 14-to 18-Fr G-tubes and 18-Fr J-tubes assessed in these experiments are commonly used in pediatric and adult patients.
A number of diluents for bead delivery were evaluated. Deionized water was evaluated in all tube sizes (14, 16, and 18 Fr) . Ketocal® (Nutricia, Gaithersburg, MD, U.S.A.), apple juice, and sparkling water were used in the smaller 14-Fr G-tubes to assess if they may lessen the chances of tube clogging; theses diluents were selected based upon their potential glidant properties, as well as recommendations from external clinicians regarding what diluents are often used with patients in their clinical practice. Ketocal is a nutritionally dense formula used to administer the classic ketogenic diet (4:1 ratio of fat:carbohydrate + protein) for dietary management of intractable epilepsy [8] . The dilution scheme for feeding tube experiments is summarized in Table 1 .
Study design
The overall experimental method was as follows. First, the G-and Jtubes were flushed with 15-mL deionized water prior to USL255 bead delivery. The number of beads per 100-mg USL255 (four 25-mg capsules) were counted and recorded. The total dose of USL255 was divided, and each portion was suspended in 15 mL of diluent in a small beaker. While using a swirling motion, suspended beads were gently pushed through a primed, appropriately sized irrigation syringe attached to the medication port of the feeding tube. For all G-tube experiments, 60-mL irrigation syringes were used while a 35-mL irrigation syringe was used for the 18-Fr J-tube experiment. The process of delivering each bead portion via gentle pressure method was repeated until all bead portions from the total dose were delivered. Next, the beaker was rinsed with 10-mL portions of diluent (15-mL portions were used for sparkling water experiments) and poured into the syringe until no beads remained in the beaker; the total volume used was then recorded. Following rinsing of the beaker, the number of beads remaining in the syringe and tube were recorded. Finally, the tube was then flushed with an additional 15-mL diluent and the number of beads in the syringe and tube after flushing was recorded.
Data analyses
Experimental procedures were performed in triplicate and acceptance criteria was defined as percent recovery of no less than 98% of beads transferred for each replicate (Eq. (1)).
Percent recovery ¼ 100 Â n 0 −n f ð Þ =n 0 n 0 ¼ initial number of beads n f ¼ number of beads observed on tubing=syringe A total of 36 healthy adults were randomized to 1 of 4 treatment sequences. Their demographics are presented in Table 2 .
Of the 36 randomized study participants, 29 (80.6%) completed the entire 4-arm study, including 2 additional treatment periods not described here (Table 2) . A total of 33 participants received USL255 200 mg sprinkled or administered intact (i.e., safety population) and had sufficient samples for accurate estimation of PK parameters (i.e., PK population). Bioequivalence of treatments was assessed in all of the 31 participants who received single doses of both USL255 sprinkled and intact (i.e., bioequivalence population).
Plasma topiramate concentrations
Mean plasma concentration-time profiles were similar following a single dose of USL255 200 mg sprinkled or administered intact for the participants with sufficient samples for PK estimates (Fig. 1) .
Pharmacokinetic evaluations of USL255 demonstrated that the mean AUC, C max , and t 1/2 values were similar when USL255 was sprinkled or the capsule was administered intact (Table 3 ). Median T max was 4 h earlier for USL255 sprinkled compared with that for the intact section) . b A total of 7 participants discontinued early due to protocol noncompliance (n = 4), lost to follow-up (n = 2), and personal reasons (n = 1). capsule (p = 0.0018). The 90% CI of the GLSM ratio (sprinkled:intact) for AUC and C max were within the 0.80-1.25 equivalence limits, demonstrating that USL255 sprinkled onto applesauce was bioequivalent to the intact capsule (Table 3) .
Safety and tolerability of USL255
USL255 was generally well tolerated, with similar TEAEs reported after administration of USL255 200-mg capsule sprinkled or administered intact (Table 4 ). All TEAEs were either mild or moderate in intensity, and most were deemed related to treatment. Of the TEAEs observed in ≥5% of participants in either treatment group, nausea, paresthesia, dizziness, and headache were the most commonly reported (Table 4) . There were no deaths or TEAEs that led to study discontinuation.
Other than the single event of hypotension, there were no clinically important findings on vital sign, ECG, or physical examination assessments. Overall, mean hematology and serum chemistry parameters were within reference ranges, and no differences were observed between the two treatment periods. No participants had clinically meaningful changes in C-SSRS evaluations during the study.
3.3.
In vitro delivery of USL255 beads via enteral feeding tubes 3.3.1. 14-Fr G-tubes: bead recovery and dosing volume using multiple diluents A 100-mg dose of USL255 diluted in deionized water clogged the 14-Fr G-tube, even at the lowest concentration (5-mg topiramate/15-mL deionized water); as such, more concentrated dilutions were not evaluated. Diluting USL255 beads in apple juice at the highest concentration of 25 mg/15 mL was generally successful, with an average of 99.7% bead recovery in 113-mL dosing volume. In 1 replicate with apple juice, the 14-Fr G-tube clogged during the final beaker wash but was easily dislodged. USL255 beads diluted at 25 mg/15 mL in sparkling water resulted in 100% bead recovery in 220-mL dosing volume, though a small fraction of beads in each dose stuck to the beaker or floated in the diluent due to carbonation, making it difficult to transfer to the syringe. USL255 bead recovery with Ketocal was successful for all dilution schemes with no tube clogging in 14-Fr G-tubes (Table 5 ).
16 and 18-Fr G-tubes and 18-Fr J-tubes: bead recovery and dosing volume using deionized water
Recovery of USL255 100 mg in 25-mg/15-mL portions, with deionized water as the diluent, resulted in clogging the 16-Fr G-tube. In these tubes, bead recovery was successful at half the concentration (12.5 mg/15 mL; Table 5 ). Diluting USL255 100 mg with deionized water in 25-mg/15-mL portions was successful for the 18-Fr G-tube and 18-Fr J-tube, with bead recovery at or above 99.6% and dosing volume ranging from 100 to 120 mL for all doses and concentrations evaluated (Table 5 ).
Discussion
The purpose of this publication was to provide additional information on the clinical utility of USL255, particularly for individuals with swallowing difficulties. The two studies presented here focused on different properties of the USL255 capsule. In the first, the bioequivalence of USL255 sprinkled and administered intact was evaluated in healthy participants. In the second study, varying conditions to pass USL255 beads through enteral feeding tubes in order to minimize bead clogging were assessed in vitro, including multiple diluents, bead dilutions, and tube sizes. Together, these studies provide information that can be used by clinicians when treating patients of all ages with swallowing difficulties.
Bioequivalence of USL255 beads sprinkled onto applesauce versus the intact capsule postovernight fast
In the phase 1 study in healthy adults presented here, USL255 sprinkled demonstrated bioequivalence with the intact capsule for both AUC and C max and similar t 1/2 , indicating that the two administration methods provide similar topiramate exposure. The plasma concentration-time profile also indicated that sprinkling did not impact the XR properties of USL255.
Median T max was earlier for USL255 sprinkled (10 h) compared with that for the intact capsule (14 h); however, this is not entirely unexpected, as ingestion of the beads without the capsule shell may lead to faster absorption. This is supported by a PK study of XR morphine, in which mean T max was~4.5 h faster with the sprinkle dose versus the intact Bioequivalence for AUC and C max was established if the 90% CI for GLSM ratio of sprinkled:intact were contained between 0.80 and 1.25. AUC 0-t , area under the plasma concentration-time curve from time 0 to last measurable time point; AUC 0-∞ , area under the plasma concentration-time curve from time 0 to infinity; CI, confidence interval; C max , maximum plasma concentration; GLSM, geometric leastsquares mean; SD, standard deviation; t 1/2 , terminal elimination half-life; T max , time to maximum plasma concentration. a n = 31 (bioequivalence population). b n = 32. c n = 29. d Wilcoxon signed-rank test was used for nonparametric comparison of T max values (p = 0.0018).
Table 4
Summary of TEAEs reported during the study for either treatment (safety population). capsule [16] , similar to the median difference observed in this study. It is important to note, however, that the statistically significant difference in USL255 T max is not expected to be clinically significant, as there was no effect on the bioequivalence of C max or AUC. Additionally, slight differences in T max would not be expected to impact the overall efficacy of a once-daily drug used chronically for the treatment of epilepsy. Similar TEAEs were reported after administration of USL255 200-mg capsule sprinkled or administered intact. The most common TEAEs in either treatment group were nausea, paresthesia, dizziness, and headache, and all TEAEs were mild or moderate in intensity. These adverse events were not unexpected for topiramate and have been observed in previous studies of USL255, both in healthy participants and in patients with epilepsy [9] [10] [11] 14, 17] .
The ability to sprinkle the beads contained within the USL255 capsule may be particularly useful for children or elderly patients who tend to have a high incidence of epilepsy and swallowing difficulties [3, 4] . Children often have difficulties swallowing capsules or tablets until 6 years of age, and approximately 15% of elderly patients experience dysphagia [18] , which can result from aging as well as the effects of concomitant medications or comorbid medical conditions (e.g., stroke) [5, 6] . While many immediate-release AEDs offer drug formulations that may be well suited for patients with swallowing difficulties (e.g., oral suspensions or sprinkle capsules), only 3 XR AEDs-carbamazepine, divalproex sodium, and USL255-have been developed in a sprinkle formulation [17] . These may be the most optimal for patients with swallowing difficulties, as XR formulations offer the convenience of reduced dosing frequency and pill burden with the advantage of a sprinkle administration route. Of the currently available topiramate formulations, USL255 is the only XR topiramate sprinkle formulation. Additionally, it is the only XR topiramate approved for monotherapy or adjunctive treatment of POS, PGTC seizures, and/or Lennox-Gastaut syndrome in children ≥2 years of age, which includes the age range of children who may not be able to swallow tablets/capsules. Thus, the option to sprinkle USL255 beads onto soft food provides a potential alternative for a variety of patients with epilepsy who have difficulties swallowing.
A limitation of this single-dose study is that the bioequivalence data were obtained from healthy adults and not in patients with epilepsy, which may exhibit differences in drug absorption, distribution, metabolism, and excretion. Additionally, as this study evaluated PK following a single-dose of USL255, the impact of sprinkle on AUC, C max , and T max following steady-state administration has not be evaluated. However, single-dose studies are generally recommended by the US FDA to assess bioequivalence because they tend to be more sensitive than steadystate studies.
Delivery of USL255 beads via enteral feeding tubes
Optimized treatment options are also important for the subpopulation of patients with epilepsy in which feeding tubes may be surgically implanted [7] due to swallowing difficulties secondary to neurological comorbidities [8] . Patients who require feeding tubes may also benefit from treatment with XR AEDs that reduce the number of times per day that medication is passed through the feeding tube, which may aid caregivers and patients alike.
The in vitro experiments reported here showed that USL255 bead recovery was nearly 100% in ≥14-Fr G-tubes and 18-Fr J-tubes evaluated, and tube clogging was prevented by portioning the dose and using a glidant diluent for smaller diameter tubes. These exploratory in vitro analyses provide the first insight into the potential for USL255 bead delivery via enteral feeding tubes.
A limitation of these evaluations is that they were not performed in patients with feeding tubes. Maintenance of seizure control, the safety profile, and optimal procedure for delivering USL255 beads through feeding tubes have yet to be determined in patients with epilepsy. Overall, there are limited publications evaluating the delivery of AED sprinkle formulations via feeding tubes. In a 1992 study, Jones-Saete et al. administered valproate sprinkle (VPA-S) to 8 patients (7 children, 1 adult) with feeding tubes of either the standard Foley "mushroom" or "button" type [19] . Delivery of a VPA-S "slurry" in 1 oz of formula was allowed to run in by gravity, and was then flushed with remaining formula. Within weeks to months after therapy with VPA-S, 4 of the 8 patients had leakage, which was controlled in 3 patients by replacement of the tube and/or use of a larger catheter. The authors hypothesized that the higher incidence of leakage with VPA-S was caused by deposition of undissolved particles on the surface of the exterior tube, but noted that leaking complications in patients are minor and usually manageable [19] . Though alternative methods of bead delivery were not evaluated in the VPA-S study, in 2002, Riss et al. assessed the delivery of XR carbamazepine via enteral feeding tubes in a set of in vitro experiments and a small clinical study (N = 6, patients 6-20 years of age) [20] . When testing different diluents (deionized water, apple juice, or a nutritional supplement) and connectors (straight or angled) in 14-to 24-Fr G-tubes during the in vitro experiments, Riss et al. reported that clogging was most likely to occur when using right-angled enteral feeding tubes (not tested in our study), and when using deionized water or apple juice versus the nutritional supplement [20] . During the clinical study, 4 of the 6 patients were successfully given XR carbamazepine via feeding tubes with little occlusion. The dosing volumes used in their in vitro experiments were much smaller than those used in the experiments for USL255, which may explain the increased clogging they observed. Moreover, Riss et al. did not evaluate portioning the dose, as was done here, which may be particularly important for minimizing clogging during feeding tube delivery of AEDs [20] .
Conclusions
A single dose of a USL255 200-mg capsule sprinkled onto applesauce was generally safe and well tolerated, and demonstrated bioequivalence to the intact capsule. In vitro delivery of USL255 beads via enteral feeding tubes was examined as an alternative delivery route in large-bore (≥14 Fr) feeding tubes commonly used in pediatric and adult patients. Using a diluent with glidant properties (e.g., Ketocal, apple juice, sparkling water), essentially 100% of beads passed through 14-Fr G-tubes; deionized water and portioning of dose resulted in 100% bead delivery in 16-Fr G-tubes and 18-Fr G-and J-tubes. The multiparticulate formulation of USL255, Qudexy® XR (topiramate) extended-release capsules, offers an important alternative for those patients who may be unable to swallow intact capsules.
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